RAs, originally for diabetes, may impact brain health, finding potential benefits for dementia and addiction but inconsistent ...

Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance ...

Researchers concluded that the GLP-1RA showed no ability to slow disease progression in people living with Parkinson’s ...

UK: A recent consensus statement from leading UK medical organizations—including the Association of Anaesthetists, the ...

As the body of research expands on the potential of glucagon-like peptide-1 receptor agonists to address various health ...

Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...

Intercontinental Exchange and RELX are among the stocks that are now expensive. We sell different types of products and services to both investment professionals and individual investors. These ...

These drugs, called GLP1-RAs (short for glucagon-like peptide-1 receptor agonists), have been found to reduce hospital visits ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its ...

Sodium-glucose cotransporter 2, or SGLT2, inhibitors and glucagon-like peptide ... a GLP-1 receptor agonist up to 2 years before conception were less likely to develop hypertensive disorders ...